Primary CNS Lymphoma (PCNSL): Market View

• In 2024 and 2029, Urban China is anticipated to have the highest number of diagnosed prevalent cases of PCNSL, representing a large proportion of global cases.
• Currently, PCNSL treatment relies mostly on off-label agents, and the Bruton's tyrosine kinase (BTK) inhibitors currently available to treat refractory/relapsed (r/r) PCNSL cases.
• The PCNSL pipeline holds 43 molecules, with no assets in the pre-registration stage, one asset in Phase III development, and another 23 in Phase II.
• Over the past decade, 171 clinical trials have been conducted in PCNSL. The year with the most studies initiated was 2021 (26 trials) followed by 2020 (24 trials).
• During the past 20 months, six mergers and acquisitions and 11 strategic alliances involving companies developing PCNSL assets were completed globally.
• There remains a significant unmet need, which is driving pipeline development of BTK inhibitors and novel cell therapies to improve outcomes.

Report Scope

Components of the report include:

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Primary CNS Lymphoma Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Primary CNS Lymphoma Therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.